Happy Friday, readers!
Light: It’s a particle. It’s a wave. Could it also be a cancer treatment?
Rakuten CEO Mickey Mikitani sure thinks so. The serial entrepreneur entered the world of biotech following a devastating pancreatic cancer diagnosis for his father back in 2012. The tragedy spurred him to seek unique solutions to the cancer scourge--including a highly unusual approach called “photoimmunotherapy.”
"One of my friends called me, who was also a friend of my father"s... and said, by the way, my cousin is doing this new project, trying to cure cancer with light," Mikitani explained during a one-on-one interview at our Fortune Brainstorm Health conference on Wednesday. "I was like, this must be a joke. But I was desperate."
Mikitani’s father was eventually taken by the illness. But that didn’t stop him from evangelizing this form of cancer therapy, which involves infusing patients with an “antibody-drug conjugate” (i.e., a pairing of an antibody that makes its way to tumors and a drug that can attack said tumors), and then activating the tumor-killing process with the use of near-infrared light.
Rakuten Aspyrion already has several treatments using this photoimmunotherapy platform in both early- and late-stage clinical trials. "I was ignorant enough to bet on this one," he says of his unconventional approach.
Read on for the day’s news, and have a wonderful weekend.
The money in gene editing. (Fortune)
Sanofi preps for more layoffs. (FiercePharma)
Microsoft and Google Face Employee Protests, by Ellen McGirt
Why Accenture Bought a Digital Ad Agency, by Adam Lashinsky
SEC Guidance Sparks Fear and Loathing in Crypto Industry, by Jeff John Roberts
[ceo_attribution author="Produced by Sy Mukherjee" email="[email protected]" twitter="the_sy_guy"] Find past coverage. Sign up for other Fortune newsletters.